JP2021500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500025A5
JP2021500025A5 JP2020521880A JP2020521880A JP2021500025A5 JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5 JP 2020521880 A JP2020521880 A JP 2020521880A JP 2020521880 A JP2020521880 A JP 2020521880A JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
stands
galnac
nucleotides
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020521880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500025A (ja
JP7353276B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056801 external-priority patent/WO2019079781A2/en
Publication of JP2021500025A publication Critical patent/JP2021500025A/ja
Publication of JP2021500025A5 publication Critical patent/JP2021500025A5/ja
Priority to JP2023151506A priority Critical patent/JP7645323B2/ja
Application granted granted Critical
Publication of JP7353276B2 publication Critical patent/JP7353276B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020521880A 2017-10-20 2018-10-19 Ｂ型肝炎感染の治療方法 Active JP7353276B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023151506A JP7645323B2 (ja) 2017-10-20 2023-09-19 Ｂ型肝炎感染の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575358P 2017-10-20 2017-10-20
US62/575,358 2017-10-20
PCT/US2018/056801 WO2019079781A2 (en) 2017-10-20 2018-10-19 METHODS OF TREATING HEPATITIS B TYPE INFECTIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023151506A Division JP7645323B2 (ja) 2017-10-20 2023-09-19 Ｂ型肝炎感染の治療方法

Publications (3)

Publication Number Publication Date
JP2021500025A JP2021500025A (ja) 2021-01-07
JP2021500025A5 true JP2021500025A5 (https=) 2023-07-21
JP7353276B2 JP7353276B2 (ja) 2023-09-29

Family

ID=66173915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521880A Active JP7353276B2 (ja) 2017-10-20 2018-10-19 Ｂ型肝炎感染の治療方法
JP2023151506A Active JP7645323B2 (ja) 2017-10-20 2023-09-19 Ｂ型肝炎感染の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023151506A Active JP7645323B2 (ja) 2017-10-20 2023-09-19 Ｂ型肝炎感染の治療方法

Country Status (30)

Country Link
US (5) US10799524B2 (https=)
EP (2) EP3684377B1 (https=)
JP (2) JP7353276B2 (https=)
KR (1) KR102783206B1 (https=)
CN (2) CN111372593B (https=)
AU (1) AU2018351649B2 (https=)
BR (1) BR112020007476A2 (https=)
CA (1) CA3078960A1 (https=)
CL (1) CL2020001061A1 (https=)
CO (1) CO2020005135A2 (https=)
CR (1) CR20200163A (https=)
DK (1) DK3684377T3 (https=)
ES (1) ES2936863T3 (https=)
FI (1) FI3684377T3 (https=)
HR (1) HRP20230023T1 (https=)
HU (1) HUE061122T2 (https=)
IL (4) IL282881B2 (https=)
LT (1) LT3684377T (https=)
MA (1) MA50264B1 (https=)
MX (1) MX2020004060A (https=)
MY (1) MY201698A (https=)
PE (1) PE20220561A1 (https=)
PH (1) PH12020550591A1 (https=)
PL (1) PL3684377T3 (https=)
PT (1) PT3684377T (https=)
RS (1) RS64001B1 (https=)
SG (1) SG11202003488WA (https=)
SI (1) SI3684377T1 (https=)
UA (1) UA128786C2 (https=)
WO (1) WO2019079781A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA128786C2 (uk) 2017-10-20 2024-10-23 Дайсерна Фармасьютикалз, Інк Олігонуклеотид для лікування інфекції гепатиту в
CN112534055A (zh) 2018-07-13 2021-03-19 豪夫迈·罗氏有限公司 用于调节rtel1表达的寡核苷酸
AU2020358016A1 (en) * 2019-10-02 2022-04-21 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering RNA with minimal fluorine content
JP2023506954A (ja) * 2019-12-19 2023-02-20 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
EP4081217A1 (en) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
MX2022007908A (es) * 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
AU2021318943A1 (en) * 2020-07-27 2023-03-02 Aligos Therapeutics, Inc. HBV binding oligonucleotides and methods of use
TW202221122A (zh) 2020-08-05 2022-06-01 瑞士商赫孚孟拉羅股份公司 Ｂ型肝炎患者之寡核苷酸治療
US20240124879A1 (en) * 2020-12-18 2024-04-18 Olix Pharmaceuticals, Inc. Rnai agent for inhibiting hbv expression and use thereof
CN114853829A (zh) * 2021-02-05 2022-08-05 上海拓界生物医药科技有限公司 一种核酸配体、其缀合物、制备方法及用途
CN114940991B (zh) * 2021-04-13 2023-02-03 厦门甘宝利生物医药有限公司 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用
WO2022223515A2 (en) 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
KR20240101580A9 (ko) 2021-11-11 2025-12-10 에프. 호프만-라 로슈 아게 Hbv 치료를 위한 약학 조합물
CA3235672A1 (en) * 2021-11-29 2023-06-01 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein
EP4201947A1 (en) 2021-12-22 2023-06-28 F. Hoffmann-La Roche AG Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途
US20240309383A1 (en) * 2023-02-24 2024-09-19 Suzhou Sanegene Bio Inc. Small interfering rna targeting hbv and uses thereof
WO2025199466A1 (en) 2024-03-22 2025-09-25 Purdue Research Foundation Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US20030176372A1 (en) 2001-05-04 2003-09-18 Technologie Integrale Ltd Anti-virus agent
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
DK2548438T3 (en) * 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
EP2164965B1 (en) 2007-05-29 2013-09-11 University Of The Witwatersrand, Johannesburg A primary micro rna expression cassette
DK2341943T3 (en) 2008-09-22 2019-02-25 Dicerna Pharmaceuticals Inc COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
BR112012008865A2 (pt) * 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US9029341B2 (en) * 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
RS61447B1 (sr) * 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EA024762B9 (ru) * 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
CA2893824A1 (en) * 2012-12-14 2014-06-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
CN103333890B (zh) 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CA2950960A1 (en) 2014-06-06 2015-12-10 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
CN104059916A (zh) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 乙肝病毒特异性的microRNA样siRNA序列及其用途
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
KR102545316B1 (ko) * 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
DK3569711T3 (da) 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc Ligandmodificerede dobbeltstrengede nukleinsyrer
US10689647B2 (en) * 2015-05-08 2020-06-23 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
RU2747822C2 (ru) 2016-03-14 2021-05-14 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для понижения экспрессии pd-l1
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
WO2019075419A1 (en) * 2017-10-13 2019-04-18 Dicerna Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
UA128786C2 (uk) 2017-10-20 2024-10-23 Дайсерна Фармасьютикалз, Інк Олігонуклеотид для лікування інфекції гепатиту в
TW202221122A (zh) 2020-08-05 2022-06-01 瑞士商赫孚孟拉羅股份公司 Ｂ型肝炎患者之寡核苷酸治療

Similar Documents

Publication Publication Date Title
JP2021500025A5 (https=)
JP2020536587A5 (https=)
US12303525B2 (en) Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
TW202031267A (zh) S-抗原運輸抑制寡核苷酸聚合物及方法
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
US20230119360A1 (en) Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
AU2017326372B2 (en) Modified oligonucleotides and methods of use
CN111372593A (zh) 治疗乙型肝炎感染的方法
JP2022551269A5 (https=)
KR20220148241A (ko) Pd-l1을 표적화하기 위한 방법 및 조성물
JP2023550061A (ja) オリゴヌクレオチド及びその抗ｂ型肝炎とｄ型肝炎ウイルスにおける応用
KR20240101580A (ko) Hbv 치료를 위한 약학 조합물
TW202237189A (zh) 具有增強之肝靶向的ｓ抗原運輸抑制寡核苷酸聚合物之接合物
JP2022520653A5 (https=)
EP4081217A1 (en) Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CN119662639A (zh) 抑制乙型肝炎病毒基因表达的siRNA、其缀合物和药物组合物及用途
WO2025232886A1 (zh) 一种抑制乙型肝炎病毒的寡核苷酸、缀合物、组合物及其用途
HK40110728A (zh) 用於治疗hbv的药物组合
TW202609059A (zh) 用於抑制類血管生成素蛋白-3 (ANGPTL3)表現的RNAi藥劑及組合物及使用方法
HK1077503A1 (zh) 基於核酸的化合物及其使用方法
HK1077503B (en) Nucleic acid-based compounds and methods of use thereof